Phase II Trial of Immunotherapy With Durvalumab (MEDI4736) With Continuous or Intermittent MEK Inhibitor Selumetinib in KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Durvalumab (Primary) ; Selumetinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Mar 2018 Planned End Date changed from 1 Apr 2023 to 1 May 2024.
- 12 Mar 2018 Planned primary completion date changed from 1 Apr 2023 to 1 May 2023.
- 12 Mar 2018 Planned initiation date changed from 1 Apr 2018 to 1 May 2018.